A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
Public ClinicalTrials.gov record NCT00811018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.
Study identification
- NCT ID
- NCT00811018
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,192 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2003 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Jul 2011 (Actual)
- Last update posted
- Apr 24, 2012
2003 – 2011
United States locations
- U.S. sites
- 45
- U.S. states
- 25
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Birmingham | Alabama | 35294 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85013 | — |
| Pfizer Investigational Site | Los Angeles | California | 90073 | — |
| Pfizer Investigational Site | San Francisco | California | 94143-0124 | — |
| Pfizer Investigational Site | Torrence | California | 90502 | — |
| Pfizer Investigational Site | Denver | Colorado | 80218 | — |
| Pfizer Investigational Site | Denver | Colorado | 80262 | — |
| Pfizer Investigational Site | Sarasota | Florida | 34233 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30322 | — |
| Pfizer Investigational Site | Augusta | Georgia | 30912 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30030 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Kansas City | Kansas | 66160 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112-1393 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | Portland | Maine | 04102 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21205 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02111 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02118 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02218 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109-0570 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | New Brunswick | New Jersey | 08903-0019 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43210 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29425 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232-2650 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232-5735 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232 | — |
| Pfizer Investigational Site | Galveston | Texas | 77555-0561 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84143 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53215 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00811018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2012 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00811018 live on ClinicalTrials.gov.